Captor Therapeutics Announces Clinical Candidate for Project CT-03!
Captor Therapeutics, a biopharmaceutical company developing drugs based on Targeted Protein Degradation (TPD),announced on Monday, September 24, 2024, the selection of a clinical candidate in its latest project.
CT-03 is the second most advanced project being conducted by Captor, where preclinical studies have been completed with very promising results. Data from studies conducted on crab-eating macaques indicate a wide therapeutic window for the potential drug, particularly in the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow. We consider this candidate to be "first-in-class" as it is currently the only MCL-1 protein degrader under development in the pharmaceutical market. This innovative therapy, based on the induction of apoptosis in cancer cells, is expected to provide not only high efficacy but also a high level of safety.
The company's next step will be to submit the necessary IND/CTA documentation to initiate clinical trials, planned for late 2025.
